Immunohistochemical Changes After Neoadjuvant Chemotherapy and Their Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2025.10.017 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Marcelo Antonini und 20 weiteren Autor:innen. Beteiligte Einrichtung: Hospital do Servidor Público Estadual Francisco Morato de Oliveira, São Paulo, Brazil; BBREAST Group - Brazilian Breast Cancer Association Team, São …. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Biomarkers, Tumor, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Changes in immunohistochemical (IHC) profiles following neoadjuvant chemotherapy (NAC) may impact therapeutic decisions and prognosis in breast cancer patients. However, the clinical significance of these biomarker conversions remains uncertain. To evaluate the frequency of IHC marker conversion (estrogen receptor [ER], progesterone receptor [PR], and HER2) after NAC and its association with pathological complete response (pCR), overall survival (OS), and disease-free survival (DFS). We conducted a systematic review and meta-analysis of cohort studies reporting pre- and post-NAC IHC profiles in breast cancer. A comprehensive search was performed in PubMed, Embase, Scopus, and Web of Science. The ROBINS-I tool was used to assess risk of bias. Random-effects models were applied to calculate pooled conversion rates and assess the prognostic impact of IHC changes. Twenty-four studies (n = 5891 patients) were included. The pooled conversion rates were 9.2% for ER, 15.1% for PR, 8.6% for HER2. Loss of hormone receptor positivity was associated with a lower pCR rate and worse DFS (HR 1.42; 95% CI, 1.11-1.81). HER2 gain correlated with improved pCR. High heterogeneity was observed, and sensitivity analyses confirmed the robustness of the results. IHC profile changes after NAC are frequent and clinically relevant. Loss of hormone receptor expression may indicate poorer prognosis, while HER2 gain suggests improved treatment sensitivity. Reassessment of IHC markers post-NAC should be considered to optimize adjuvant therapy decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital do Servidor Público Estadual Francisco Morato de Oliveira, São Paulo, Brazil; BBREAST Group - Brazilian Breast Cancer Association Team, São Paulo, Brazil.
- BBREAST Group - Brazilian Breast Cancer Association Team, São Paulo, Brazil; Centro de Referência da Saúde da Mulher, Hospital da Mulher, São Paulo, Brazil.
- Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address: facina@unifesp.br.
- BBREAST Group - Brazilian Breast Cancer Association Team, São Paulo, Brazil; Hospital Geral de Fortaleza, Fortaleza, Ceará, Brazil.
- BBREAST Group - Brazilian Breast Cancer Association Team, São Paulo, Brazil; Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil; Oncoclínicas, Porto Alegre, Rio Grande…
- BBREAST Group - Brazilian Breast Cancer Association Team, São Paulo, Brazil; Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
Zitieren
APA
Antonini, M., Mattar, A., Facina, G., Cavalcante, F. P., Zerwes, F., Brenelli, F. P., Frasson, A. L., Millen, E. C., Campos, R. C., Félix, L. X., Vieira, J. C., Teixeira, M. D., Madeira, M., Fenile, R., Couto, H. L., Soares, L. R., Junior, R. F., Arakelian, R., Leite, R. M., …, & Gebrim, L. H. (2026). Immunohistochemical Changes After Neoadjuvant Chemotherapy and Their Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.10.017
Vancouver
Antonini M, Mattar A, Facina G, Cavalcante FP, Zerwes F, Brenelli FP, et al. Immunohistochemical Changes After Neoadjuvant Chemotherapy and Their Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.10.017
BibTeX
@article{Antonini2026,
author = {Antonini, Marcelo and Mattar, André and Facina, Gil and Cavalcante, Francisco Pimentel and Zerwes, Felipe and Brenelli, Fabricio Palermo and Frasson, Antônio Luis and Millen, Eduardo Camargo and Campos, Rodrigo Caires and Félix, Letícia Xavier and Vieira, Juliana Calado and Teixeira, Marina Diógenes and Madeira, Marcelo and Fenile, Rogério and Couto, Henrique Lima and Soares, Leonardo Ribeiro and Junior, Ruffo de Freitas and Arakelian, Renata and Leite, Renata Montarroyos and Rocha, Vitoria Rassi Mahamed and Gebrim, Luiz Henrique},
title = {Immunohistochemical Changes After Neoadjuvant Chemotherapy and Their Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2025.10.017}
}
EUVIMED